このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

個別化された外因性界面活性剤を送達するための呼吸メカニクス (REMEDIES)

2026年11月2日 更新者:Anna Lavizzari、Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

界面活性剤療法のための振動力学対酸素化ベースの基準のランダム化比較試験

This study is an interventional, non-pharmacological, multicentric, randomized, controlled, superiority, non-profit study. Its primary objective is to evaluate if the administration of surfactant based on FOT assessment will allow a 5-day reduction in the duration of respiratory support as compared to standard practice in preterm infants between 27+0 and 32+6 weeks' gestation. The secondary objectives are:

  1. to determine if a lung mechanics-based approach for administering surfactant will change treatment timing; and
  2. to assess the impact of the novel approach on other neonatal general outcomes. The study will take place within the neonatal intensive care units. Non-invasive respiratory support will be delivered by nasal CPAP with a starting pressure of 5-8 cmH2O. FiO2 will be titrated in order to achieve the target SpO2 91-95%.

Infants matching the clinical criteria for inclusion will be randomized in two arms following the current data protection and confidentiality regulations. Central, computer-generated randomization (allocation 1:1) with variable block sizes according to gestational age will be used. Infants will be stratified according to gestational age (27+0 -28+6 weeks; 29+0 -30+6 weeks; 31+0 -32+6 weeks) and center.

Study Arms:

A) Surfactant administration following oxygenation-based criteria (clinical assessment) (control) B) Surfactant administration following both lung mechanics assessment OR oxygenation-based criteria (clinical assessment) (intervention).

調査の概要

研究の種類

介入

入学 (推定)

458

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Milan、イタリア
        • 募集
        • Fondazione IRCCs Cà Granda Ospedale Maggiore Policlinico
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

6ヶ月~7ヶ月 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Gestational age (GA) ≥ 27+0 and < 33+0 weeks
  2. Spontaneously breathing infants, requiring non-invasive respiratory support (nasal CPAP or bilevel nasal CPAP). Criteria for commencement of non-invasive respiratory support: FiO2 >0.30 for target SpO2 88-93% or Silverman score ≥ 5.
  3. Inborn
  4. Written parental consent obtained
  5. Administration of Caffeine bolus 20 mg/kg IV or PO as per standard care

Exclusion Criteria:

  1. Major congenital anomalies
  2. Need of intubation in delivery suite according to the AAP guidelines for neonatal resuscitation or early at the admission in NICU (within one hour from birth).
  3. Surfactant therapy prior to the study entry
  4. Severe birth asphyxia, defined by APGAR score ≤ 5 at 10 minutes after birth OR continued need for resuscitation 10 minutes after birth OR pH < 7.0 or base excess (BE) < -12 mmol/l on umbilical cord or on an arterial or capillary blood sample obtained within 1 hour from birth OR moderate to severe encephalopathy
  5. Respiratory failure secondary to conditions other that RDS as identified by lung imaging (air leaks, lung malformations…)
  6. Any clinical condition which may place the infants at undue risk as deemed by clinicians
  7. Participation to trials with competitive outcomes or likely to have an impact on the primary outcome of the study
  8. Outborn patients

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:A/Control

Surfactant administration following clinical assessment

Surfactant is administered following oxygenation-based criteria

実験的:B/Intervention

Surfactant administration following both lung mechanics assessment and clinical assessment

Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O*s /L

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Days of respiratory support
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of required respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

二次結果の測定

結果測定
メジャーの説明
時間枠
First surfactant administration
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Time of first surfactant administration (in hours)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of non-invasive respiratory support
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of non-invasive respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of invasive respiratory support
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of invasive respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Patients intubated and mechanically ventilated
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of patients intubated and mechanically ventilated

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Patients receiving multiple surfactant doses
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of patients receiving multiple surfactant doses

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days on supplemental oxygen
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days on supplemental oxygen

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Total cumulative oxygen exposure
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Total cumulative oxygen exposure computed as the time integral of the FiO2 values

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants receiving more than 28 days of respiratory support
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants receiving more than 28 days of respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing BPD
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing BPD according to the definition by NICHD 2016

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing air-leaks
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing air-leaks

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing prematurity-associated complications
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing prematurity-associated complications (severe intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), sepsis, retinopathy of prematurity (ROP), patent ductus arteriosus requiring pharmacological or surgical treatment)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants discharged home with oxygen or respiratory support
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants discharged home with oxygen or respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days to achieve full-enteral feeding
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days to achieve full-enteral feeding (160 ml/kg/day of milk intake)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of hospitalization
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of hospitalization

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants receiving postnatal steroids
時間枠:From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants receiving postnatal steroids

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年12月15日

一次修了 (推定)

2028年5月30日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2022年12月9日

QC基準を満たした最初の提出物

2023年3月28日

最初の投稿 (実際)

2023年3月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • Sperimentazione 3115
  • Studio Numero 6379 (その他の識別子:Comitato Etico Milano Area 2)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する